The Experts below are selected from a list of 1590 Experts worldwide ranked by ideXlab platform
K Kashiwabara - One of the best experts on this subject based on the ideXlab platform.
-
prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma related antigen and Cytokeratin 19 Fragment levels
Clinica Chimica Acta, 2000Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined differences in the 2-year survival rate in bronchogenic squamous cell carcinoma patients with normal serum levels of both Cytokeratin 19 Fragment (CYFRA 21-1) and squamous cell carcinoma-related antigen (SCC) (NL group, n=15), patients with only increased SCC levels (SCC+ group, n=14), patients with only increased CYFRA 21-1 levels (CYFRA+ group, n=14), and patients with elevated levels of both CYFRA 21-1 and SCC (EL group, n=65). The 2-year survival rates for the CYFRA+ and the EL group were lower than those for the SCC+ group and the NL group (0 and 12.9% vs. 66.7 and 85.6%, log rank: p<0.0001, Wilcoxon: p<0.0001). However, there were no differences between the rate for the SCC+ and the NL group and between that for the CYFRA+ and the EL group. Serum carcinoembryonic antigen (CEA) levels increased in the patients with the elevated CYFRA 21-1 levels. This results suggest that there may be some differences between squamous cell carcinoma patients with increased CYFRA 21-1 levels and those with normal levels and that it is CYFRA 21-1 levels, not SCC levels, that relate to the prognosis.
-
Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and Cytokeratin 19 Fragment levels.
Clinica chimica acta; international journal of clinical chemistry, 2000Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined differences in the 2-year survival rate in bronchogenic squamous cell carcinoma patients with normal serum levels of both Cytokeratin 19 Fragment (CYFRA 21-1) and squamous cell carcinoma-related antigen (SCC) (NL group, n=15), patients with only increased SCC levels (SCC+ group, n=14), patients with only increased CYFRA 21-1 levels (CYFRA+ group, n=14), and patients with elevated levels of both CYFRA 21-1 and SCC (EL group, n=65). The 2-year survival rates for the CYFRA+ and the EL group were lower than those for the SCC+ group and the NL group (0 and 12.9% vs. 66.7 and 85.6%, log rank: p
-
serum Cytokeratin 19 Fragment levels in non small cell lung cancer patients according to t factor in the tnm classification
Clinica Chimica Acta, 1999Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined changes in Cytokeratin 19 Fragment (CYFRA 21-1) levels in relation to the T factor in 64 non-small cell N2M0 lung cancer patients. Although a correlation between the levels and T factor was found (ρ=0.627, p<0.0001), there was no difference between the levels in T3 and T4. Serum CYFRA 21-1 levels increased in the order of the following groups: the limited tumor group (T1+T2: n=28), the group with tumor extending to the pleura or chest wall (T3: n=13), and the group with tumor invading into the mediastinum (T4: n=12). The level was lower in the group with malignant pleural effusion (T4: n=11) than in the group with tumor invading into the mediastinum (6.7±4.7 ng/ml vs. 12.2±8.1 ng/ml, p=0.0046). We suspect that the presence of malignant pleural effusion is not directly related to the three-dimensional expansion of the tumor and this is a reason why CYFRA 21-1 levels in T4 are not higher than those in T3.
-
Serum Cytokeratin 19 Fragment levels in non-small cell lung cancer patients according to T factor in the TNM classification.
Clinica chimica acta; international journal of clinical chemistry, 1999Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined changes in Cytokeratin 19 Fragment (CYFRA 21-1) levels in relation to the T factor in 64 non-small cell N2M0 lung cancer patients. Although a correlation between the levels and T factor was found (rho=0.627, p
-
correlation between serum Cytokeratin 19 Fragment and tissue polypeptide antigen levels in patients with non malignant diseases
Clinica Chimica Acta, 1998Co-Authors: K Kashiwabara, H Nakamura, Toshio Kiguchi, Takeshi MatsuokaAbstract:It has been reported that Cytokeratin 19 Fragment (CYFRA 21-1) is superior to tissue polypeptide antigen (TPA) as a tumor marker, although there is a high correlation between CYFRA 21-1 and TPA levels in patients with lung cancer. We investigated correlations between these tumor markers in patients with non-malignant diseases. Marked correlations were found between CYFRA 21-1 and TPA levels in healthy subjects (n=31), non-insulin-dependent diabetes mellitus (n=160) and hemodialysis patients (n=83) (range of r-value=0.90–0.93, P<0.0001). However in liver cirrhosis patients (n=36), only a weak correlation was found (r=0.39, P<0.0001) and there were correlations between only TPA and both aspartate aminotransferase and alanine aminotransferase levels (r2=0.48 and 0.36, P<0.0001). The elevated TPA levels in liver cirrhosis patients may be related to the decreased specificity of TPA as a tumor marker.
H Nakamura - One of the best experts on this subject based on the ideXlab platform.
-
prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma related antigen and Cytokeratin 19 Fragment levels
Clinica Chimica Acta, 2000Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined differences in the 2-year survival rate in bronchogenic squamous cell carcinoma patients with normal serum levels of both Cytokeratin 19 Fragment (CYFRA 21-1) and squamous cell carcinoma-related antigen (SCC) (NL group, n=15), patients with only increased SCC levels (SCC+ group, n=14), patients with only increased CYFRA 21-1 levels (CYFRA+ group, n=14), and patients with elevated levels of both CYFRA 21-1 and SCC (EL group, n=65). The 2-year survival rates for the CYFRA+ and the EL group were lower than those for the SCC+ group and the NL group (0 and 12.9% vs. 66.7 and 85.6%, log rank: p<0.0001, Wilcoxon: p<0.0001). However, there were no differences between the rate for the SCC+ and the NL group and between that for the CYFRA+ and the EL group. Serum carcinoembryonic antigen (CEA) levels increased in the patients with the elevated CYFRA 21-1 levels. This results suggest that there may be some differences between squamous cell carcinoma patients with increased CYFRA 21-1 levels and those with normal levels and that it is CYFRA 21-1 levels, not SCC levels, that relate to the prognosis.
-
Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and Cytokeratin 19 Fragment levels.
Clinica chimica acta; international journal of clinical chemistry, 2000Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined differences in the 2-year survival rate in bronchogenic squamous cell carcinoma patients with normal serum levels of both Cytokeratin 19 Fragment (CYFRA 21-1) and squamous cell carcinoma-related antigen (SCC) (NL group, n=15), patients with only increased SCC levels (SCC+ group, n=14), patients with only increased CYFRA 21-1 levels (CYFRA+ group, n=14), and patients with elevated levels of both CYFRA 21-1 and SCC (EL group, n=65). The 2-year survival rates for the CYFRA+ and the EL group were lower than those for the SCC+ group and the NL group (0 and 12.9% vs. 66.7 and 85.6%, log rank: p
-
serum Cytokeratin 19 Fragment levels in non small cell lung cancer patients according to t factor in the tnm classification
Clinica Chimica Acta, 1999Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined changes in Cytokeratin 19 Fragment (CYFRA 21-1) levels in relation to the T factor in 64 non-small cell N2M0 lung cancer patients. Although a correlation between the levels and T factor was found (ρ=0.627, p<0.0001), there was no difference between the levels in T3 and T4. Serum CYFRA 21-1 levels increased in the order of the following groups: the limited tumor group (T1+T2: n=28), the group with tumor extending to the pleura or chest wall (T3: n=13), and the group with tumor invading into the mediastinum (T4: n=12). The level was lower in the group with malignant pleural effusion (T4: n=11) than in the group with tumor invading into the mediastinum (6.7±4.7 ng/ml vs. 12.2±8.1 ng/ml, p=0.0046). We suspect that the presence of malignant pleural effusion is not directly related to the three-dimensional expansion of the tumor and this is a reason why CYFRA 21-1 levels in T4 are not higher than those in T3.
-
Serum Cytokeratin 19 Fragment levels in non-small cell lung cancer patients according to T factor in the TNM classification.
Clinica chimica acta; international journal of clinical chemistry, 1999Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined changes in Cytokeratin 19 Fragment (CYFRA 21-1) levels in relation to the T factor in 64 non-small cell N2M0 lung cancer patients. Although a correlation between the levels and T factor was found (rho=0.627, p
-
correlation between serum Cytokeratin 19 Fragment and tissue polypeptide antigen levels in patients with non malignant diseases
Clinica Chimica Acta, 1998Co-Authors: K Kashiwabara, H Nakamura, Toshio Kiguchi, Takeshi MatsuokaAbstract:It has been reported that Cytokeratin 19 Fragment (CYFRA 21-1) is superior to tissue polypeptide antigen (TPA) as a tumor marker, although there is a high correlation between CYFRA 21-1 and TPA levels in patients with lung cancer. We investigated correlations between these tumor markers in patients with non-malignant diseases. Marked correlations were found between CYFRA 21-1 and TPA levels in healthy subjects (n=31), non-insulin-dependent diabetes mellitus (n=160) and hemodialysis patients (n=83) (range of r-value=0.90–0.93, P<0.0001). However in liver cirrhosis patients (n=36), only a weak correlation was found (r=0.39, P<0.0001) and there were correlations between only TPA and both aspartate aminotransferase and alanine aminotransferase levels (r2=0.48 and 0.36, P<0.0001). The elevated TPA levels in liver cirrhosis patients may be related to the decreased specificity of TPA as a tumor marker.
T Esaki - One of the best experts on this subject based on the ideXlab platform.
-
prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma related antigen and Cytokeratin 19 Fragment levels
Clinica Chimica Acta, 2000Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined differences in the 2-year survival rate in bronchogenic squamous cell carcinoma patients with normal serum levels of both Cytokeratin 19 Fragment (CYFRA 21-1) and squamous cell carcinoma-related antigen (SCC) (NL group, n=15), patients with only increased SCC levels (SCC+ group, n=14), patients with only increased CYFRA 21-1 levels (CYFRA+ group, n=14), and patients with elevated levels of both CYFRA 21-1 and SCC (EL group, n=65). The 2-year survival rates for the CYFRA+ and the EL group were lower than those for the SCC+ group and the NL group (0 and 12.9% vs. 66.7 and 85.6%, log rank: p<0.0001, Wilcoxon: p<0.0001). However, there were no differences between the rate for the SCC+ and the NL group and between that for the CYFRA+ and the EL group. Serum carcinoembryonic antigen (CEA) levels increased in the patients with the elevated CYFRA 21-1 levels. This results suggest that there may be some differences between squamous cell carcinoma patients with increased CYFRA 21-1 levels and those with normal levels and that it is CYFRA 21-1 levels, not SCC levels, that relate to the prognosis.
-
Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and Cytokeratin 19 Fragment levels.
Clinica chimica acta; international journal of clinical chemistry, 2000Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined differences in the 2-year survival rate in bronchogenic squamous cell carcinoma patients with normal serum levels of both Cytokeratin 19 Fragment (CYFRA 21-1) and squamous cell carcinoma-related antigen (SCC) (NL group, n=15), patients with only increased SCC levels (SCC+ group, n=14), patients with only increased CYFRA 21-1 levels (CYFRA+ group, n=14), and patients with elevated levels of both CYFRA 21-1 and SCC (EL group, n=65). The 2-year survival rates for the CYFRA+ and the EL group were lower than those for the SCC+ group and the NL group (0 and 12.9% vs. 66.7 and 85.6%, log rank: p
-
serum Cytokeratin 19 Fragment levels in non small cell lung cancer patients according to t factor in the tnm classification
Clinica Chimica Acta, 1999Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined changes in Cytokeratin 19 Fragment (CYFRA 21-1) levels in relation to the T factor in 64 non-small cell N2M0 lung cancer patients. Although a correlation between the levels and T factor was found (ρ=0.627, p<0.0001), there was no difference between the levels in T3 and T4. Serum CYFRA 21-1 levels increased in the order of the following groups: the limited tumor group (T1+T2: n=28), the group with tumor extending to the pleura or chest wall (T3: n=13), and the group with tumor invading into the mediastinum (T4: n=12). The level was lower in the group with malignant pleural effusion (T4: n=11) than in the group with tumor invading into the mediastinum (6.7±4.7 ng/ml vs. 12.2±8.1 ng/ml, p=0.0046). We suspect that the presence of malignant pleural effusion is not directly related to the three-dimensional expansion of the tumor and this is a reason why CYFRA 21-1 levels in T4 are not higher than those in T3.
-
Serum Cytokeratin 19 Fragment levels in non-small cell lung cancer patients according to T factor in the TNM classification.
Clinica chimica acta; international journal of clinical chemistry, 1999Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined changes in Cytokeratin 19 Fragment (CYFRA 21-1) levels in relation to the T factor in 64 non-small cell N2M0 lung cancer patients. Although a correlation between the levels and T factor was found (rho=0.627, p
Wenqi Dong - One of the best experts on this subject based on the ideXlab platform.
-
A magnetic nanoparticle-based time-resolved fluoroimmunoassay for determination of the Cytokeratin 19 Fragment in human serum.
Journal of fluorescence, 2015Co-Authors: Guanfeng Lin, Tian-cai Liu, Jing-yuan Hou, Zhi-qi Ren, Jian-wei Zhou, Qian-ni Liang, Zhenhua Chen, Wenqi DongAbstract:A sensitive, rapid and novel measurement method for Cytokeratin 19 Fragment (CYFRA 21-1) in human serum by magnetic particle-based time-resolved fluoroimmunoassay (TRFIA) is described. Built on a sandwich-type immunoassay format, analytes in samples were captured by one monoclonal antibody coating onto the surface of magnetic beads and "sandwiched" by another monoclonal antibody labeled with europium chelates. The coefficient variations of the method were lower than 7%, and the recoveries were in the range of 90-110% for serum samples. The lower limit of quantitation of the present method for CYFRA 21-1 was 0.78 ng/ml. The correlation coefficient of CYFRA 21-1 values obtained by our novel TRFIA and CLIA was 0.980. The present novel TRFIA demonstrated high sensitivity, wider effective detection range and excellent reproducibility for determination of CYFRA 21-1 can be useful for early screening and prognosis evaluation of patients with non-small cell lung cancer.
-
simultaneous determination of the Cytokeratin 19 Fragment and carcinoembryonic antigen in human serum by magnetic nanoparticle based dual label time resolved fluoroimmunoassay
RSC Advances, 2014Co-Authors: Guanfeng Lin, Tian-cai Liu, Jing-yuan Hou, Zhi-qi Ren, Hui Zhao, Wenhua Huang, Wenqi DongAbstract:A highly sensitive, rapid and novel simultaneous measurement method for Cytokeratin 19 Fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) in human serum by magnetic nanoparticle-based dual-label time-resolved fluoroimmunoassay was developed. On the basis of a sandwich-type immunoassay format, analytes in the samples were captured by antibodies coated onto the surface of the magnetic beads and sandwiched by other antibodies labeled with europium and samarium chelates. The lower limit of quantitation of the present method for CYFRA 21-1 was 0.77 ng mL−1 and CEA was 0.85 ng mL−1. The coefficient variations of the method were less than 7%, and the recoveries were in the range of 90–110% for serum samples. The concentrations of CYFRA 21-1 and CEA serum samples determined by the present method were compared with those obtained by the chemiluminescence immunoassay. A good correlation was obtained with the correlation coefficients of 0.961 for CYFRA 21-1 and 0.938 for CEA. This novel method demonstrated high sensitivity, wide effective detection range and excellent reproducibility for the simultaneous determination of CYFRA 21-1 and CEA, which can be useful for the early screening and prognosis evaluation of patients with lung cancer.
Shigefumi Suehiro - One of the best experts on this subject based on the ideXlab platform.
-
Non-Small Cell Lung Cancer Clinical Value of Serum Cytokeratin 19 Fragment and Sialyl-Lewis X in
2013Co-Authors: Takuma Tsukioka, Kiyotoshi Inoue, Masao Kameyama, Shigefumi Suehiro, Shinjiro Mizuguchi, Noritoshi Nishiyama, Takashi Iwata, Tatsuya NishidaAbstract:DOI:€10.1016/j.athoracsur.2006.08.042 Ann Thorac Surg 2007;83:216-221 Izumi, Takuma Tsukioka, Kiyotoshi Inoue, Masao Kameyama and Shigefumi Suehiro Shinjiro Mizuguchi, Noritoshi Nishiyama, Takashi Iwata, Tatsuya Nishida, NobuhiroNon-Small Cell Lung Cancer Clinical Value of Serum Cytokeratin 19 Fragment and Sialyl-Lewis X inhttp://ats.ctsnetjournals.org/cgi/content/full/83/1/216 located on the World Wide Web at: The online version of this article, along with updated information and services, is
-
Serum Sialyl Lewisx and Cytokeratin 19 Fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer
Lung cancer (Amsterdam Netherlands), 2007Co-Authors: Shinjiro Mizuguchi, Takahiro Uenishi, Takuma Tsukioka, Kiyotoshi Inoue, Noritoshi Nishiyama, Takashi Iwata, Tatsuya Nishida, Nobuhiro Izumi, Kenichi Wakasa, Shigefumi SuehiroAbstract:This study aimed to establish the clinical significance of preoperative serum Cytokeratin 19 Fragment (CYFRA21-1) and Sialyl Lewis(x) (SLX) in patients with stage I non-small cell lung cancer (NSCLC). The study involved 137 patients (87 male, 50 female; median age 69 years) with completely resected stage I NSCLC. SLX, carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and CYFRA21-1 were examined. Receiver operator characteristic (ROC) curves were constructed to determine prognostic cut-off values. Among the 137 patients, we identified 30 with recurrence within 3 years. The 5-year survival rates in patients with (n=30) and without (n=107) recurrence were 14% and 81%, respectively. The serum concentrations of SLX, CEA, and CYFRA21-1 in the recurrence group were significantly higher than those in the non-recurrence group. The areas under the ROC curve (AUC) were 0.72, 0.65, 0.53, and 0.64 for SLX, CEA, SCC, and CYFRA21-1, respectively. The prognostic cut-off values were 36U/ml, 7.8ng/ml, 1.5ng/ml, and 3.2ng/ml for SLX, CEA, SCC, and CYFRA21-1, respectively. A log-rank test revealed that age, performance status, T factor, lymphatic invasion, vascular invasion, SLX, CEA, SCC, and CYFRA21-1 were all significantly associated with survival. By multivariate analysis, age, performance status, lymphatic invasion, SLX (risk ratio, 4.11) and CYFRA21-1 (risk ratio, 3.47) were independent prognostic factors. For patients positive for both CYFRA21-1 and SLX, the relative risk was 5.32 compared with patients who were negative for both markers. The 5-year survival rates were 80% in the group negative for both markers (n=86); 52% in the group positive for one of the markers (n=43); and 13% for the group positive for both markers (n=8) (p
-
clinical value of serum Cytokeratin 19 Fragment and sialyl lewis x in non small cell lung cancer
The Annals of Thoracic Surgery, 2007Co-Authors: Shinjiro Mizuguchi, Takuma Tsukioka, Kiyotoshi Inoue, Masao Kameyama, Noritoshi Nishiyama, Takashi Iwata, Tatsuya Nishida, Nobuhiro Izumi, Shigefumi SuehiroAbstract:Background This study aimed to establish the clinical significance of preoperative serum Cytokeratin 19 Fragment (CYFRA21-1) and sialyl-Lewis x (SLex) as prognostic markers. Methods The study involved 272 patients (181 male, 91 female; median age 69 years; range, 32 to 92) with non-small cell lung cancer (NSCLC) who underwent pulmonary resection with mediastinal lymph node dissection. Tumor markers carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), CYFRA21-1, and SLex were examined. Results A log-rank test revealed that age, gender, performance status, CEA, SCC, CYFRA21-1, and SLex were associated with the survival rate. By multivariate analysis, age, gender, performance status, CYFRA21-1 (risk ratio, 2.42) and SLex (risk ratio, 6.18) were independent prognostic factors. For patients positive for both markers, the relative risk was 6.10 compared with patients negative for both markers. The patients were divided into three groups: negative for both CYFRA21-1 and SLex (n = 97); positive for either marker (n = 136); and positive for both markers (n = 39). The 1-, 3-, and 5-year survival rates were the following: 98%, 82%, and 75% in the first group; 90%, 63%, and 49% in the second group; and 62%, 31%, and 25% in the third group ( p Conclusions Serum CYFRA21-1 and SLex were prognostic markers for NSCLC. Their combination should contribute to the classification of NSCLC patients. Preoperative staging should be carefully performed in patients positive for both tumor markers.
-
Clinical Value of Serum Cytokeratin 19 Fragment and Sialyl-Lewis X in Non-Small Cell Lung Cancer
The Annals of thoracic surgery, 2007Co-Authors: Shinjiro Mizuguchi, Takuma Tsukioka, Kiyotoshi Inoue, Masao Kameyama, Noritoshi Nishiyama, Takashi Iwata, Tatsuya Nishida, Nobuhiro Izumi, Shigefumi SuehiroAbstract:This study aimed to establish the clinical significance of preoperative serum Cytokeratin 19 Fragment (CYFRA21-1) and sialyl-Lewis x (SLex) as prognostic markers. The study involved 272 patients (181 male, 91 female; median age 69 years; range, 32 to 92) with non-small cell lung cancer (NSCLC) who underwent pulmonary resection with mediastinal lymph node dissection. Tumor markers carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), CYFRA21-1, and SLex were examined. A log-rank test revealed that age, gender, performance status, CEA, SCC, CYFRA21-1, and SLex were associated with the survival rate. By multivariate analysis, age, gender, performance status, CYFRA21-1 (risk ratio, 2.42) and SLex (risk ratio, 6.18) were independent prognostic factors. For patients positive for both markers, the relative risk was 6.10 compared with patients negative for both markers. The patients were divided into three groups: negative for both CYFRA21-1 and SLex (n = 97); positive for either marker (n = 136); and positive for both markers (n = 39). The 1-, 3-, and 5-year survival rates were the following: 98%, 82%, and 75% in the first group; 90%, 63%, and 49% in the second group; and 62%, 31%, and 25% in the third group (p < 0.001). Sixty-four percent of patients positive for both markers were histologic stage III/IV, and 68% of patients negative for both markers were stage I. Serum CYFRA21-1 and SLex were prognostic markers for NSCLC. Their combination should contribute to the classification of NSCLC patients. Preoperative staging should be carefully performed in patients positive for both tumor markers.
